“Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma”
News
A collaboration between Bristol-Myers Squibb and AbbVie Biotherapeutics is making possible a Phase 3 clinical study to treat patients with refractory multiple myeloma. The treatment, lenalidomide and dexamethasone with elotuzumab, ... Read more